Yeh ETH, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy. Circulation. 2004;109(25):3122–31.

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer. 2013;49(6):1374–403.

Pizzino F, Vizzari G, Bomzer CA, Qamar R, Carerj S, Zito C, Khandheria BK. Diagnosis of chemotherapy-induced cardiotoxicity. J Patient Cent Res. Rev.; 2014; 1:121-27.

Raj, S., Franco, V. I., & Lipshultz, S. E. Anthracycline-induced cardiotoxicity: A review of pathophysiology, diagnosis, and treatment. Current Treatment Options in Cardiovascular Medicine. 2014; 16(6). 315-414.

Van der Zanden, S. Y., Qiao, X., & Neefjes, J. New insights into the activities and toxicities of the old anticancer drug doxorubicin. In FEBS Journal. 2021; (Vol. 288, Issue 21). 15-583.

Brana, L., & Tabernero, J. Cardiotoxicity. Annals of Oncology. 2010; 21(SUPPL. 7), 173-179.

Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol. 2018; 15: 335-346.

Sano M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol. 2018;71: 471-476.

Yang S., Henikoff F., Teves, and Kemp. ‘Doxorubicin, DNA torsion, and chromatin dynamics.’ Biochimica et Biophysica Acta - Reviews on Cancer. The Authors. 2014; 1845(1), pp. 84–89.

Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. and Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004; 56(2), pp.185 -229.

Zhu, H., Sarkar, S., Scott, L., Danelisen, L., Trush, M.A., Jia, Z. and Li, R.Y. Doxorubicin Redox Biology: Redox Cycling, Topoisomerase Inhibition, and Oxidative Stress. Reactive Oxygen Species, 2016; 1(3), 189-198.

Abboud SH, Hadi NR, Assad HC, et al. Cardioprotective effects of erythropoietin against doxorubicin-induced cardiotoxicity in rats. World Heart J 2017; 9(3): 221–230.

KN, A. K., NS, B., MC, S., & KC, S. (2020). Degree-based topological indices on asthma drugs with QSPR analysis during covid-19. European Journal of Molecular & Clinical Medicine, 7(10), 53–66.

Sheibani, M., Azizi, Y., Shayan, M. et al. Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches. Cardiovasc Toxicol. 2022; 22, 292–310.

Wang XY, Yang CT, Zheng DD, et al. (2012) Hydrogen sulfide protects H9c2 cells against doxorubicin-induced cardiotoxicity through inhibition of endoplasmic reticulum stress. Mol Cell Biochem, 363(1–2):419–426.

Laredj, L.N., Licitra, F., Puccio, H.M. The molecular genetics of coenzyme Q biosynthesis in health and disease. Biochimie. 2014; 100, 78- 87.

Holmberg, M. J., Uber, A., Stankovic, N., Chen, C. O., Grossestreuer, A. V., Donnino, M. W., et al. Ubiquinol (reduced coenzyme Q10) and cellular oxygen consumption in patients undergoing coronary artery bypass grafting. Journal of Intensive Care Medicine. 2018; 1, 885066618789114.

Fouad, A. A., & Jresat, I. Hepatoprotective effect of coenzyme Q10 in rats with acetaminophen toxicity. Environmental Toxicology and Pharmacology. 2012; 33, 158–167.

Zhai, J., Bo, Y., Lu, Y., Liu, C., & Zhang, L. Effects of coenzyme Q10 on markers of inflammation: A systematic review and meta-analysis. PLoS ONE. 2017; 12, e0170172.

Jafari, M., Mousavi, S. M., Asgharzadeh, A., & Yazdani, N. Coenzyme Q10 in the treatment of heart failure: A systematic review of systematic reviews. Indian Heart Journal. 2018;7–0, 111–117.

Kawamukai M. Biosynthesis of coenzyme Q in eukaryotes. Biosci Biotechnol Biochem. 2016; 80:23–33.

Tran U, Clarke C. Endogenous synthesis of coenzyme Q in eukaryotes. Mitochondrion. 2007;7: S62–71.

Kumar A, Kaur H, Devi P, Mohan V. Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension, and Meniere-like syndrome. Pharmacol Ther. 2009; 124:259–68.

Bentinger M, Tekle M, Dallner G. "Coenzyme Q--biosynthesis and functions." Biochemical and Biophysical Research Communications. 2010;396 (1): 74–9.

Hathcock JN, Shao A. "Risk assessment for coenzyme Q10 (Ubiquinone)". Regulatory Toxicology and Pharmacology. 2006;45 (3): 282–8.

Abdelkareem Aljumaily, S. A., Demir, M., Elbe, H et al. Antioxidant, anti-inflammatory, and anti-apoptotic effects of crocin against doxorubicin-induced myocardial toxicity in rats. Environmental Science and Pollution Research. 2021; 28(46), 65802-65813.

Hekmat, A. S., Navabi, Z, Alipanah, H. et al. Alamandine significantly reduces doxorubicin-induced cardiotoxicity in rats. Human and Experimental Toxicology. 2021; 40(10), 1781-1795.

Botelho, A. F. M., Lempek, M. R., Branco, S. E. M., Nogueira, M. M., de Almeida, M. E., Costa, A. G., ... & Melo, M. M. Coenzyme Q10 cardioprotective effects against doxorubicin-induced cardiotoxicity in Wistar Rat. Cardiovascular Toxicology. 2020; 20(3), 222-234.

Xue, R., Wang, J., Yang, L., Liu, X., Gao, Y., Pang, Y., Wang, Y., & Hao, J. Coenzyme Q10 Ameliorates Pancreatic Fibrosis via the ROs-triggered mTOR Signaling Pathway. Oxidative medicine and cellular longevity, 2019;8039694.

Oliveira, M. S., Melo, M. B., Carvalho, J. L., Melo, I. M., Lavor, M. S., Gomes, D. A., de Goes, A. M., & Melo, M. M. Doxorubicin Cardiotoxicity and Cardiac Function Improvement After Stem Cell Therapy Diagnosed by Strain Echocardiography. Journal of cancer science & therapy. 2013;5(2), 52–57.

Albakaa, R. N., Rizij, F. A., & Hassan, R. M. A. Potential Role of Empagliflozin to Ameliorate Doxorubicin Induced Cardiotoxicity in Male Rats, 2023.

Mobaraki, M., Faraji, A., Zare, M., Dolati, P., Ataei, M., & Manshadi, H. D. Molecular mechanisms of cardiotoxicity: a review on a major side-effect of doxorubicin. Indian J. Pharm. Sci. 2017; 79, 335-344.‏

Yu J.L.; Jin, Y.; Cao, X.Y.; Gu, H.H. Dexmedetomidine Alleviates Doxorubicin Cardiotoxicity by Inhibiting Mitochondrial Reactive Oxygen Species Generation. Hum. Cell. 2020; 33, 47–56.

Chen, P. Y., Hou, C. W., Shibu, M. A., Day, C. H., Pai, P., Liu, Z. R., ... & Huang, C. Y. Protective effect of Co‐enzyme Q10 On doxorubicin‐induced cardiomyopathy of rat hearts. Environmental toxicology. 2017; 32(2), 679-689.

Shabaan, D. A., Mostafa, N., El-Desoky, M. M., & Arafat, E. A. Coenzyme Q10 protects against doxorubicin-induced cardiomyopathy via antioxidant and anti-apoptotic pathways. Tissue Barriers. 2023; 11(1), 2019504.

Zhao L. Protective effects of trimetazidine and coenzyme Q10 on cisplatin-induced cardiotoxicity by alleviating oxidative stress and mitochondrial dysfunction. Anatolian journal of cardiology. 2019; 22(5), 232–239.

Kuzmicic J, Parra V, Verdejo HE, Lopez-Crisosto C, Chiong M, Garcia L, et al. Trimetazidine prevents palmitate-induced mitochondrial fission and dysfunction in cultured cardiomyocytes. Biochem Pharmacol. 2014; 91:323–36.

Kido K, Ito H, Yamamoto Y, Makita K, Uchida T. Cytotoxicity of propofol in human induced pluripotent stem cell-derived cardiomyocytes. J Anesth. 2018; 32:120–31.

Aryal B, and Rao VA. Deficiency in cardiolipin reduces doxorubicin-induced oxidative stress and mitochondrial damage in human B-lymphocytes. PLoS ONE. 2016;11(7): e0158376.

Byrne, N. J., Rajasekaran, N. S., Abel, E. D., & Bugger, H. Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy. Free Radical Biology and Medicine. 2021; 169(March), 317–342.

Cecerska-Heryć, E., Surowska, O., Heryć, R., Serwin et al. Are antioxidant enzymes essential markers in the diagnosis and monitoring of cancer patients – A review? Clinical Biochemistry. 2021;93(March), 1–8.

Mustafa, H. N., Hegazy, G. A., El Awdan, S. A., & Abdelbaset, M. Protective role of CoQ10 or L-carnitine on the integrity of the myocardium in doxorubicin-induced toxicity. Tissue and Cell. 2017; 49(3), 410-426.

Conklin, K. A. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integrative Cancer Therapies. 2005; 4(2), 110-130.

Sun, Z., Yan, B., Yu, W.Y., Yao, X., Ma, X., Sheng, G., Ma, Q. Vitexin attenuates acute doxorubicin cardiotoxicity in rats via the suppression of oxidative stress, inflammation, and apoptosis and the activation of FOXO3a. Exp Ther Med. 2016; 12, 1879-1884.

Elsherbiny, N.M., Salama, M.F., Said, E., El-Sherbiny, M., Al-Gayyar, M.M. Crocin protects against doxorubicin-induced myocardial toxicity in rats through down-regulation of inflammatory and apoptotic pathways. Chem Biol Interact. 2016; 247, 39-48.

Tsuneki, H., Tokai, E., Suzuki, T., Seki, T., Okubo, K., Wada, T., ... & Sasaoka, T. Protective effects of coenzyme Q10 against angiotensin II-induced oxidative stress in human umbilical vein endothelial cells. European journal of pharmacology. 2013; 701(1-3), 218-227.

Xie, T., Wang, C., Jin, Y., Meng, Q., Liu, Q., Wu, J., & Sun, H. CoenzymeQ10-induced activation of AMPK-YAP-OPA1 pathway alleviates atherosclerosis by improving mitochondrial function, inhibiting oxidative stress, and promoting energy metabolism. Frontiers in pharmacology. 2020; 11, 1034.‏